Европейски съюз -
български -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
България -
български -
Изпълнителна агенция по лекарствата
sunitinib mylan 12,5 mg hard capsules
12,5 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib mylan 25 mg hard capsules
25 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib mylan 50 mg hard capsules
50 mg hard capsules
Европейски съюз -
български -
EMA (European Medicines Agency)
sutent
pfizer limited - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
България -
български -
Изпълнителна агенция по лекарствата
sunitinib alvogen 12,5 mg hard capsules
12,5 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib alvogen 25 mg hard capsules
25 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib alvogen 37,5 mg hard capsules
37,5 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib alvogen 50 mg hard capsules
50 mg hard capsules
България -
български -
Изпълнителна агенция по лекарствата
sunitinib sandoz 12,5 mg hard capsules
12,5 mg hard capsules